You are here

Accipio Detects Brain Bleeds, Receives FDA 510(k) Clearance

AI Software Helps Physicians Prioritize Patients with Hemorrhagic Stroke or Intracranial Trauma

MaxQ AI (formerly MedyMatch, Tel Aviv, Israel) has received FDA 510(k) marketing clearance for Accipio, an artificial intelligence software that can rapidly detect brain bleeds in computerized tomography (CT) scans.

The software medical device is designed to be acutely sensitive to the presence of intracranial bleeding in the scans, and alerts the treating physician when bleeding is detected. The tool could help relieve physicians and emergency health care providers from high caseloads, rendering speedy diagnoses for patients in greatest need.

Accipio’s ability to detect suspected brain bleeds so speedily is ground-breaking. The potential impact is huge: saving just one patient from acute stroke in the 13,000 hospitals in the U.S. and Europe would bring about some $2 billion in savings in one year.

There are plans to also use the software in mobile stroke units. This would enable staff to differentiate between ischemic and hemorrhagic strokes and administer clot-dissolving drugs to the patient while en route to the hospital.

Sources: Mobihealthnews, November 12, 2018.

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations